1. Home
  2. CUBI vs IMNM Comparison

CUBI vs IMNM Comparison

Compare CUBI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Customers Bancorp Inc

CUBI

Customers Bancorp Inc

HOLD

Current Price

$76.47

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.07

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUBI
IMNM
Founded
1994
2006
Country
United States
United States
Employees
869
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CUBI
IMNM
Price
$76.47
$18.07
Analyst Decision
Buy
Strong Buy
Analyst Count
8
10
Target Price
$85.00
$32.80
AVG Volume (30 Days)
275.2K
1.2M
Earning Date
04-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$24.95
N/A
Revenue Next Year
$9.50
$1,127.34
P/E Ratio
$11.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$50.25
$7.96
52 Week High
$82.56
$27.65

Technical Indicators

Market Signals
Indicator
CUBI
IMNM
Relative Strength Index (RSI) 54.86 33.00
Support Level $71.61 $16.81
Resistance Level $79.11 $19.16
Average True Range (ATR) 1.82 0.92
MACD 0.32 -0.21
Stochastic Oscillator 62.70 1.24

Price Performance

Historical Comparison
CUBI
IMNM

About CUBI Customers Bancorp Inc

Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: